There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on GenMark (GNMK) and Novavax (NVAX) with bullish sentiments.
GenMark (GNMK)
In a report released today, Michael Matson from Needham reiterated a Buy rating on GenMark, with a price target of $22.00. The company’s shares closed last Tuesday at $19.10, close to its 52-week high of $19.83.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 9.6% and a 58.1% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
Currently, the analyst consensus on GenMark is a Strong Buy with an average price target of $19.25, a 1.7% upside from current levels. In a report issued on July 23, Canaccord Genuity also maintained a Buy rating on the stock with a $17.00 price target.
See today’s analyst top recommended stocks >>
Novavax (NVAX)
In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Novavax, with a price target of $257.00. The company’s shares closed last Tuesday at $157.30, close to its 52-week high of $159.97.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 12.6% and a 49.0% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Novavax with a $196.00 average price target, which is a 25.2% upside from current levels. In a report issued on July 22, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $148.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NVAX:
